First-Ever mRNA vaccine for chlamydia enters human testing
NCT ID NCT06891417
Summary
This study is testing a new mRNA vaccine designed to prevent chlamydia infection. It will involve 1,560 healthy adults aged 18 to 29 who are at higher risk for sexually transmitted infections. Researchers will give different vaccine doses to assess safety and see if it triggers an immune response that protects against chlamydia.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHLAMYDIA TRACHOMATIS IMMUNIZATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site Number : 0360001
RECRUITINGAlbion, Queensland, 4010, Australia
-
Investigational Site Number : 0360002
RECRUITINGBruce, Australian Capital Territory, 2617, Australia
-
Investigational Site Number : 0360003
RECRUITINGSouthport, Queensland, 4222, Australia
-
Investigational Site Number : 0360004
RECRUITINGMorayfield, Queensland, 4506, Australia
-
Investigational Site Number : 0360005
RECRUITINGSydney, New South Wales, 2010, Australia
-
Investigational Site Number : 0360006
RECRUITINGMaroubra, New South Wales, 2035, Australia
-
Investigational Site Number : 0360010
RECRUITINGMelbourne, Victoria, 3000, Australia
Conditions
Explore the condition pages connected to this study.